EXEL earnings date and last-quarter result: last quarter beat, P/E 17.62. Updated 2026-07-23.
Exelixis (EXEL) Research Hub
Exelixis (EXEL) trades on NASDAQ, US in the Healthcare (Biotechnology) sector. As of 2026-10-26, shares last closed at 65.11 USD (+0.90%), in a range — insufficient history for 200-DMA. Valuation: trailing P/E 17.62, market cap 13.90B. This hub links to the full technical, earnings and options research available for EXEL.
Last updated 2026-10-26 · Source: end-of-day prices (adjusted); indicators computed by SniperIQ
| Sector | Healthcare (Biotechnology) |
|---|---|
| Exchange | NASDAQ, US |
| Last close | 65.11 USD (+0.90%) |
| 52-week range | 49.97 USD – 65.58 USD |
| Trend regime | Range |
| 14-day RSI | 83.1 (Overbought) |
| Trailing P/E | 17.62 |
| Market cap | 13.90B |
| Dividend yield | 0.00% |
Available research for EXEL
Covered Call on EXEL: how it works, illustrative setup around the real 65.11 USD price, max profit/loss, breakeven and when to use it. Educational.
Iron Condor on EXEL: how it works, illustrative setup around the real 65.11 USD price, max profit/loss, breakeven and when to use it. Educational.
Protective Put on EXEL: how it works, illustrative setup around the real 65.11 USD price, max profit/loss, breakeven and when to use it. Educational.
EXEL technical analysis: range, last 65.11 USD, RSI 83.1, 52w range 49.97 USD–65.58 USD, real support/resistance. Updated 2026-10-26.
More on SniperIQ
Frequently asked questions
What sector is EXEL in?
Exelixis (EXEL) is classified under Healthcare (Biotechnology), listed on NASDAQ, US.
Is EXEL in an uptrend or downtrend?
As of 2026-10-26, EXEL is in a range — insufficient history for 200-DMA. See the full technical research page for support and resistance levels.
What is EXEL's trailing P/E ratio?
EXEL's trailing P/E is 17.62, with a market cap of 13.90B. See the earnings research page for full valuation detail.